Psychiatry Research: Neuroimaging
Volume 174, Issue 2 , Pages 152-157 , 30 November 2009

Midline and right frontal brain function as a physiologic biomarker of remission in major depression

Received 19 March 2008 ,Revised 24 April 2009 ,Accepted 24 April 2009.

References 

  1. Anderer P, Saletu B, Pascual-Marqui RD. Effect of the 5-HT(1A) partial agonist buspirone on regional brain electrical activity in man: a functional neuroimaging study using low-resolution electromagnetic tomography (LORETA). Psychiatry Research: Neuroimaging. 2000;100:81–96
  2. Asada H, Fukuda Y, Tsunoda S, Yamaguchi M, Tonoike M. Frontal midline theta rhythms reflect alternative activation of prefrontal cortex and anterior cingulate cortex in humans. Neuroscience Letters. 1999;274:29–32
  3. Bareš M, Brunovsky M, Kopeček M, Stopková P, Novák T, Kozeny J, et al. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. Journal of Psychiatric Research. 2007;41:319–335
  4. Bareš M, Brunovsky M, Kopeček M, Novák T, Stopková P, Kozeny J, et al. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. European Psychiatry. 2008;23:350–355
  5. Blackhart GC, Minnix JA, Kline JP. Can EEG asymmetry patterns predict future development of anxiety and depression? A preliminary study. Biological Psychology. 2006;72:46–50
  6. Brody AL, Barsom MW, Bota RG, Saxena S. Prefrontal–subcortical and limbic circuit mediation of major depressive disorder. Seminars in Clinical Neuropsychiatry. 2001;6:102–112
  7. Cook IA, Leuchter AF. Prefrontal changes and treatment response prediction in depression. Seminars in Clinical Neuropsychiatry. 2001;6:113–120
  8. Cook IA, O'Hara R, Uijtdehaage SHJ, Mandelkern M, Leuchter AF. Assessing the accuracy of topographic EEG mapping for determining local brain function. Electroencephalography and Clinical Neurophysiology. 1998;107:408–414
  9. Cook IA, Leuchter AF, Morgan M, Witte E, Stubbeman WF, Abrams M, et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology. 2002;27:120–131
  10. Cook IA, Leuchter AF, Morgan ML, Stubbeman W, Siegman B, Abrams M. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. Journal of Psychiatric Research. 2005;39:461–466
  11. Davidson R. Parsing affective space: perspectives from neuropsychology and psychophysiology. Neuropsychology. 1993;7:464–475
  12. Davidson RJ. Affective neuroscience and psychophysiology: toward a synthesis. Psychophysiology. 2003;40:655–665
  13. Davidson RJ, Pizzagalli D, Nitschke JB, Putnam K. Depression: perspectives from affective neuroscience. Annual Review of Psychology. 2002;53:545–574
  14. First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders — Patient Edition. Biometrics Research Department, New York State Psychiatric Institute. 1994;
  15. Fitzgerald PB, Oxley TJ, Laird AR, Kulkarni J, Egan GF, Daskalakis ZJ. An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depression. Psychiatry Research: Neuroimaging. 2006;148:33–45
  16. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry. 1991;48:851–855
  17. Gotlib IH. EEG alpha asymmetry, depression, and cognitive functioning. Cognition and Emotion. 1998;12:449–478
  18. Hjorth B. EEG analysis based on time domain properties. Electroencephalography and Clinical Neurophysiology. 1970;29:306–310
  19. Hjorth B. An on-line transformation of EEG scalp potentials into orthogonal source derivations. Electroencephalography and Clinical Neurophysiology. 1975;39:526–530
  20. Hunter AM, Leuchter AF, Morgan ML, Cook IA, Abrams M, Siegman B, et al. Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo. Neuropsychopharmacology. 2005;30:792–799
  21. Hunter AM, Leuchter AF, Morgan ML, Cook IA. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. American Journal of Psychiatry. 2006;163:1426–1432
  22. Hunter AM, Ravikumar S, Cook IA, Leuchter AF. Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression. Acta Psychiatrica Scandinavica. 2009;119:266–273
  23. Ishii R, Shinosaki K, Ukai S, Inouye T, Ishihara T, Yoshimine T, et al. Medial prefrontal cortex generates frontal midline theta rhythm. Neuroreport. 1999;10:675–679
  24. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. Journal of Affective Disorders. 1998;50:97–108
  25. Keller MB. Remission versus response: the new gold standard of antidepressant care. Journal of Clinical Psychiatry. 2004;65(Suppl 4):53–59
  26. Kim SJ, Song SH, Kim JH, Kwak IS. Statistical parametric mapping analysis of the relationship between regional cerebral blood flow and symptom clusters of the depressive mood in patients with pre-dialytic chronic kidney disease. Annals of Nuclear Medicine. 2008;22:201–206
  27. Kline JP, Allen S. The failed repressor: EEG asymmetry as a moderator of the relation between defensiveness and depressive symptoms. International Journal of Psychophysiology. 2008;68:228–234
  28. Knott VJ, Lapierre YD. Computerized EEG correlates of depression and antidepressant treatment. Progress in Neuropsychopharmacology and Biological Psychiatry. 1987;11:213–221
  29. Knott VJ, Telner JI, Lapierre YD, Browne M, Horn ER. Quantitative EEG in the prediction of antidepressant response to imipramine. Journal of Affective Disorders. 1996;39:175–184
  30. Knott V, Mahoney C, Kennedy S, Evans K. Pre-treatment EEG and its relationship to depression severity and paroxetine treatment outcome. Pharmacopsychiatry. 2000;33:201–205
  31. Knott V, Mahoney C, Kennedy S, Evans K. EEG power, frequency, asymmetry and coherence in male depression. Psychiatry Research. 2001;106:123–140
  32. Knott V, Mahoney C, Kennedy S, Evans K. EEG correlates of acute and chronic paroxetine treatment in depression. Journal of Affective Disorders. 2002;69:241–249
  33. Kopeček M, Bareš M, Brunovsky M, Stopková P, Novák T, Kozeny J, et al. EEG cordance as a predictor of response to antidepressive medication — pooled analysis. In: 14th European Congress of Psychiatry, AEP, March 2006, Nice, France. 2006;
  34. Kopeček M, Sos P, Brunovsky M, Bareš M, Stopková P, Krajca V. Can prefrontal theta cordance differentiate between depression recovery and dissimulation?. Neuro Endocrinology Letters. 2007;28:524–526
  35. Kopeček M, Tislerova B, Sos P, Bareš M, Novak T, Krajca V, et al. QEEG changes during switch from depression to hypomania/mania: a case report. Neuro Endocrinology Letters. 2008;29:295–302
  36. Leuchter AF, Uijtdehaage SH, Cook IA, O'Hara R, Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Research: Neuroimaging. 1999;90:125–140
  37. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. American Journal of Psychiatry. 2002;159:122–129
  38. Leuchter AF, Morgan M, Cook IA, Dunkin J, Abrams M, Witte E. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology (Berlin). 2004;177:15–22
  39. Leuchter AF, Cook IA, DeBrota DJ, Hunter AM, Potter WZ, McGrouther CC, et al. Changes in brain function during administration of venlafaxine or placebo to normal subjects. Clinical EEG and Neuroscience. 2008;39:175–181
  40. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biological Psychiatry. 2000;48:830–843
  41. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. Journal of Clinical Psychiatry. 1998;59:608–619
  42. Milligan GW, Cooper MC. Methodological review: clustering methods. Applied Psychological Measurement. 1987;11:329–354
  43. Mirkin B. Mathematical Classification and Clustering. Dordrecht: Kluwer Academic Publishers; 1996;
  44. Mojena R. Hierarchical grouping methods and stopping rules: an evaluation. Computer Journal. 1977;20:359–363
  45. Mojtabai R. Residual symptoms and impairment in major depression in the community. American Journal of Psychiatry. 2001;158:1645–1651
  46. Morgan ML, Cook IA, Rapkin AJ, Leuchter AF. Neurophysiologic changes during estrogen augmentation in perimenopausal depression. Maturitas. 2007;56:54–60
  47. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. Journal of Clinical Psychiatry. 1999;60(Suppl 22):7–11
  48. Ormel J, Oldehinkel AJ, Nolen WA, Vollebergh W. Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. Archives of General Psychiatry. 2004;61:387–392
  49. Papakostas GI, Petersen T, Denninger JW, Tossani E, Pava JA, Alpert JE, et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. Journal of Clinical Psychopharmacology. 2004;24:507–511
  50. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychological Medicine. 1995;25:1171–1180
  51. Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biological Psychiatry. 2003;54:515–528
  52. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, Oakes TR, Larson CL, Abercrombie HC, et al. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. American Journal of Psychiatry. 2001;158:405–415
  53. Rogers MA, Kasai K, Koji M, Fukuda R, Iwanami A, Nakagome K, et al. Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neuroscience Research. 2004;50:1–11
  54. Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, Suppes T, et al. Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. Journal of Clinical Psychiatry. 1999;60:284–291
  55. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS) Clinician Rating (QIDS-C) and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry. 2003;54:573–583
  56. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine. 2006;354:1231–1242
  57. Schmidt LA. Frontal brain electrical activity in shyness and sociability. Psychological Science. 1999;10:316–320
  58. Stubbeman WF, Leuchter AF, Cook IA, Shurman BD, Morgan M, Gunay I, et al. Pretreatment neurophysiologic function and ECT response in depression. Journal of ECT. 2004;20:142–144
  59. Trivedi MH, Kern JK, Baker SM, Altshuler KZ. Computerizing medication algorithms and decision support systems for major psychiatric disorders. Journal of Psychiatric Practice. 2000;6:237–246
  60. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR⁎D: implications for clinical practice. American Journal of Psychiatry. 2006;163:28–40
  61. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine. 2006;354:1243–1252
  62. Ulrich G, Haug H, Stieglitz R, Fahndrich E. Are there distinct biochemical subtypes of depression? EEG characteristics of clinically defined on-drug responders and non-responders. Journal of Affective Disorders. 1988;15:181–185
  63. Ulrich G, Haug HJ, Stieglitz RD, Fahndrich E. EEG characteristics of clinically defined on-drug-responders and non-responders—a comparison clomipramine vs. maprotiline. Pharmacopsychiatry. 1988;21:367–368
  64. Ulrich G, Haug HJ, Fahndrich E. Acute versus chronic EEG effects of maprotiline- and in clomipramine-treated depressive inpatients and the prediction of therapeutic outcome. Journal of Affective Disorders. 1994;32:213–217
  65. Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J, Andrews G. The burden of major depression avoidable by longer-term treatment strategies. Archives of General Psychiatry. 2004;61:1097–1103
  66. Warwick JM, Carey P, Jordaan GP, Dupont P, Stein DJ. Resting brain perfusion in social anxiety disorder: a voxel-wise whole brain comparison with healthy control subjects. Progress in Neuropsychopharmacology and Biological Psychiatry. 2008;32:1251–1256
  67. Zimmerman M, Posternak MA, Chelminski I. Heterogeneity among depressed outpatients considered to be in remission. Comprehensive Psychiatry. 2007;48:113–117

PII: S0925-4927(09)00116-4

doi: 10.1016/j.pscychresns.2009.04.011

Psychiatry Research: Neuroimaging
Volume 174, Issue 2 , Pages 152-157 , 30 November 2009

Article Tools

* Image Usage & Resolution